Lisata Therapeutics (LSTA) and Kuva Labs are pleased to announce a global collaboration and license agreement. Under the terms of this agreement Kuva gains access to Lisata’s iRGD cyclic peptide product candidate, certepetide, as a targeting and enhanced delivery agent to be used with Kuva’s NanoMark platform technology. This combination creates a new class of advanced magnetic resonance imaging agents that enable the safe, non-invasive and unambiguous detection of solid tumor cancers. Under the agreement, Kuva will assume full responsibility for all research, development, and commercialization costs for NanoMark, while Lisata will be responsible for supplying certepetide. The agreement provides significant value creation for both parties and includes an upfront license fee as well as potential substantial milestone payments and royalties on future product sales to Lisata.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LSTA:
- Lisata Therapeutics Reports Q3 2024 Financial Results
- Lisata Therapeutics Reports Promising Q3 2024 Results
- Lisata Therapeutics reports Q3 EPS (59c) consensus (75c)
- Lisata Therapeutics, Valo Therapeutics enter preclinical research collaboration
- LSTA Earnings this Week: How Will it Perform?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
